Glutathione analogues in cancer treatment

David Hamilton1, Gerald Batist

  • 1Department of Pharmacology and Therapeutics, The Montreal Center for Experimental Therapeutics in Cancer, Room D127, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec, Canada H3T-1E2.

Current Oncology Reports
|January 31, 2004
PubMed

Insights

Glutathione analogues show promise in improving cancer chemotherapy by targeting cellular antioxidant systems. Further development is needed to enhance tumor specificity for better therapeutic outcomes.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Glutathione is a key intracellular antioxidant and regulator of redox potential, crucial for drug detoxification and cellular protection.
  • Alterations in the glutathione system are linked to cancer cell survival and resistance to chemotherapy drugs.

Purpose of the Study:

  • To explore the potential of glutathione analogues in enhancing cancer chemotherapy.
  • To review existing glutathione-targeting compounds and their clinical applications.

Main Methods:

  • Review of experimental and clinical studies involving glutathione analogues.
  • Analysis of compounds such as glutathione-S-transferase inhibitors, prodrugs, glyoxalase I inhibitors, and S-nitrosoglutathione.

Main Results:

  • Glutathione analogues have demonstrated promising results in experimental and clinical settings.
  • A key challenge identified is the lack of specific targeting of tumors.

Conclusions:

  • Glutathione analogues offer a potential strategy to improve cancer treatment efficacy.
  • Continued research and optimization are necessary to achieve greater tumor specificity and improve therapeutic responses in cancer patients.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...